Detail-oriented team player with strong organizational skills. Ability to handle multiple projects simultaneously with a high degree of accuracy. Goal-oriented Strength and Conditioning Coach with a solid background in designing, programming and completing team-based training to improve on-field performance. Experienced optimizing athletic performance through speed, strength and power conditioning. Strong capability at making personal connections with athletes and others to help understand their strengths and motivations and how to support them to achieve their goals.
Brock Baseball Annual Plans:
2022-2023: https://docs.google.com/spreadsheets/d/1Igf8-FKbBflvGx36YIs2R87mrRT6wEwmUXXFUuzxp7U/edit#gid=1924028248
2023-2024: https://docs.google.com/spreadsheets/d/1kRKvideuqSbO3-2QCymb1M2BP2wArxbB7S3sueOreEw/edit#gid=867282688
2023-2024 Monthly Programming (rough drafts):https://docs.google.com/spreadsheets/d/1K0QYYI4KuHw6LIfTdjF2lVeI_hC1Tj4ExQTjvjzrGUM/edit#gid=1191907105
Accepted APS Abstract: Ganglionic blockade modulates sympathetic neural discharge and neurocirculatory regulation in humans
Cameron M. Lynn1, Jacqueline K. Limberg2, Wayne T. Nicholson3, Timothy B. Curry3, Nathaniel J. Iannarelli1, J. Kevin Shoemaker4, Michael J. Joyner3, Sarah E. Baker3, Stephen A. Klassen1
1Department of Kinesiology, Brock University, St. Catharines, Ontario, Canada
2Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri, USA
3Deparment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA
4School of Kinesiology, University of Western Ontario, London, Ontario, Canada
This study investigated the impact of integrated muscle sympathetic nerve activity (MSNA) discharge patterns on human neurocirculatory regulation. In 13 healthy females (42 ± 15 years), the transduction of integrated MSNA (peroneal microneurography) into mean arterial pressure (MAP; arterial catheter) was studied during an intravenous infusion of a nicotinic ganglionic antagonist (trimethaphan camsylate, 1-7 mg/min). Neurovascular transduction (signal averaging) was studied based on the overall response, burst sequence (singlet, doublet, and triplet+), and burst amplitude (binned into tertials: small, medium, and large bursts). Data (mean ± SD) are reported for a 10-minute baseline (BSL), the one-minute period at the midpoint of the trimethaphan infusion with integrated MSNA bursts (TM-Mid), and the last minute of trimethaphan infusion with integrated MSNA bursts (TM-Last). During BSL, the MAP transduction responses were greatest for triplets+ (singlets: 0.9 ± 0.2 mmHg, doublets: 2.0 ± 0.6 mmHg, triplet+: 2.6 ± 0.9 mmHg; P < 0.01) and large bursts (small: 1.0 ± 0.3 mmHg, medium: 1.7 ± 0.5 mmHg, large: 2.2 ± 0.7 mmHg; P < 0.01). Trimethaphan infusion reduced integrated MSNA burst frequency resulting in a greater proportion of singlets (BSL: 45 ± 18 %, TM-Mid: 75 ± 23 %, TM-Last: 94 ± 20 %; P < 0.01), a lower proportion of doublets, and a lower proportion of triplets+ (BSL: 23 ± 19 %, TM-Mid: 9 ± 18 %, TM-Last: 0 ± 0 %; P < 0.01). Trimethaphan infusion reduced integrated MSNA burst amplitude resulting in a greater proportion of small bursts (BSL: 33 ± 0.2 %, TM-Mid: 60 ± 26 %, TM-Last: 78 ± 37 %; P < 0.01), a lower proportion of medium bursts, and a lower proportion of large bursts (BSL: 34 ± 1 %, TM-Mid: 17 ± 26 %, TM-Last: 1 ± 5 %; P < 0.01). Trimethaphan-mediated changes in MSNA burst frequency and amplitude were associated with reduced overall MAP transduction responses (BSL: 1.6 ± 0.5 mmHg, TM-Mid: 0.5 ± 0.2 mmHg, TM-Last: 0.3 ± 0.3 mmHg; P < 0.01). Linear regression analyses demonstrated that the trimethaphan-mediated reduction in the proportion of large bursts (β= 0.02 ± 0.008 mmHg/%, R2 = 0.13, P = 0.03) more strongly affected sympathetic neurovascular transduction responses than reductions in the proportion of triplet+ burst sequences (P = 0.91). These findings suggest that time varying MSNA discharge patterns, particularly variations in burst amplitude, support human neurocirculatory regulation.
This work was supported by the National Institutes of Health and the Natural Sciences and Engineering Research Council of Canada.